Nyrada Inc (ASX: NYR) has released a comprehensive factsheet detailing the Nyrada Xolatryp Heart Attack Trial, a Phase IIa clinical study targeting ischemia-reperfusion injury in heart attack patients. Human Research Ethics Committee (HREC) approval was received in January 2026, with first patient recruitment expected in March 2026. If successful, Xolatryp could become the first approved therapy addressing ischemia-reperfusion injury in approximately 5 million annual percutaneous coronary intervention (PCI) procedures globally.
Nyrada advances Xolatryp into Phase IIa heart attack trial
The Nyrada Xolatryp Heart Attack Trial will enrol approximately 200 patients in a 1:1 active-to-placebo ratio across multiple Australian sites. The randomised, double-blind, placebo-controlled, multicentre study is expected to commence first patient recruitment in March 2026, subject to final hospital Research Governance Office approvals.
Globally, approximately 5 million PCI procedures are performed each year, including about 50,000 in Australia. Despite PCI being the gold-standard lifesaving treatment for heart attacks, there are currently no approved therapies that address the ischemia-reperfusion injury that occurs when blocked arteries are reopened.
The trial, formally titled Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction (PROTECT-MI), is registered on ClinicalTrials.gov under identifier NCT07362446. Professor William Chan serves as Coordinating Principal Investigator.
This represents a high-value clinical milestone for Nyrada, with the potential to de-risk the asset and establish first-mover advantage in a large, unmet medical need.
When big ASX news breaks, our subscribers know first
What is ischemia-reperfusion injury and why does it matter?
Ischemia-reperfusion injury occurs when blood flow is restored to the heart following a heart attack. Although PCI (a procedure involving balloon angioplasty and stent implantation to reopen blocked arteries) is well-established and lifesaving, the sudden return of oxygenated blood paradoxically causes irreversible damage to heart muscle cells.
This cellular death results from a vicious cycle of calcium overload when the blocked artery is manually opened. There is no way to avoid reperfusion injury under current treatment protocols.
The cascade of cellular damage includes:
- Calcium overload
- Mitochondrial dysfunction
- ATP depletion
- Osmotic imbalance
- Reactive oxygen species formation
With approximately 5 million PCI procedures performed globally each year and zero approved therapies currently available to address ischemia-reperfusion injury, the market opportunity for an effective treatment is substantial. The absence of competing approved therapies positions Xolatryp as a potential first-in-class treatment in a large, established patient population with clear unmet need.
Preclinical and Phase I data support the clinical thesis
Preclinical studies in animal models of myocardial ischemia-reperfusion injury demonstrated strong cardioprotection signals across multiple dose levels. In these models, Xolatryp showed 86% cardioprotection when dosed at 30 mg/kg over 24 hours, with improved cardiac function and reductions in biomarkers including AST, LDH, and Troponin I.
At a lower dose of 9 mg/kg over 3 hours, Xolatryp achieved 42% cardioprotection, a 90% reduction in arrhythmias, and lower Troponin I levels.
The Phase I clinical trial enrolled 48 participants across six cohorts (36 active, 12 placebo) and met its primary endpoint. All doses were safe and well-tolerated, with no dose-limiting or dose-related safety issues identified. Pharmacokinetics was linear and predictable, with therapeutic levels reached within 10 minutes post-start of infusion.
| Dose | Duration | Cardioprotection | Additional Findings |
|---|---|---|---|
| 30 mg/kg | 24 hours | 86% | Improved cardiac function, reduced biomarkers (AST, LDH, Troponin I) |
| 9 mg/kg | 3 hours | 42% | 90% arrhythmia reduction, lower Troponin I |
The clean Phase I safety profile reduces clinical risk heading into Phase IIa, while the rapid onset of therapeutic levels supports the use of Xolatryp in emergency cardiac settings where time-to-treatment is critical.
Phase IIa trial design and key endpoints
The trial will enrol patients presenting with first-time ST-elevation myocardial infarction (STEMI) who are scheduled to undergo primary PCI within 6 hours of symptom onset. Male patients aged 40 to 75 years and female patients aged 55 to 75 years (or women under 55 with no possibility of pregnancy) are eligible for inclusion, provided they are haemodynamically stable.
Patients will receive intravenous Xolatryp at 3 mg/kg over approximately 6 hours or matching placebo. The primary endpoint is safety and tolerability, including cardiac-related safety parameters.
Secondary and exploratory efficacy endpoints include:
- Cardiac MRI infarct size measurement in participants with pre-PCI TIMI 0 or 1 flow
- Incidence of arrhythmias of interest
- Serum levels of Troponin I
- Pharmacokinetics in the patient population
- Day-30 patient-reported outcomes
The inclusion of cardiac MRI infarct size as an exploratory endpoint offers an objective, quantifiable efficacy signal. Cardiac MRI is considered the gold standard for measuring myocardial injury and could provide early evidence of Xolatryp’s therapeutic potential.
Trial timeline and upcoming catalysts
HREC approval was secured in January 2026, representing a significant regulatory milestone for the Nyrada Xolatryp Heart Attack Trial. First patient recruitment is expected in March 2026, subject to final individual hospital Research Governance Office approvals.
The multicentre study will be conducted across Australian sites, with Accelagen Pty. Ltd. serving as the contract research organisation.
For investors, the near-term catalyst of first patient dosed in Q1 CY2026 provides a clear milestone to track. Subsequent clinical readouts will offer de-risking data points for the investment thesis, particularly around safety and preliminary efficacy signals from exploratory endpoints.
The next major ASX story will hit our subscribers first
What success could mean for Nyrada and investors
The Nyrada Xolatryp Heart Attack Trial addresses a substantial commercial opportunity in a market with approximately 5 million PCI procedures performed globally each year and no current approved competitors in this indication.
Xolatryp (formerly NYR-BI03) is a small-molecule inhibitor of calcium-permeable TRPC 3/6/7 ion channels. By limiting pathological calcium influx, the therapy is designed to protect heart muscle cells from processes associated with irreversible injury, including mitochondrial dysfunction, ATP depletion, osmotic imbalance, and excess reactive oxygen species formation.
The TRPC platform mechanism has demonstrated potential dual application in both cardioprotection and neuroprotection, suggesting broader pipeline opportunities beyond the current cardiac indication. Phase IIa success would significantly de-risk the asset and could create partnership or licensing opportunities with larger pharmaceutical companies.
Nyrada Factsheet Conclusion
“If successful, Xolatryp has the potential to become the first drug on the market to mitigate ischemia reperfusion injury, improving heart tissue integrity and function, thereby improving outcomes for patients post-heart attack.”
The first-mover advantage in a large, established market with zero competition, combined with the platform potential extending beyond cardiac applications, positions the Nyrada Xolatryp Heart Attack Trial as a material value catalyst for (ASX: NYR) shareholders. The trial’s robust design (double-blind, placebo-controlled, multicentre) supports a clear regulatory pathway should efficacy signals emerge alongside the primary safety data.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare and biotech news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start receiving real-time alerts the moment market-moving clinical trial updates and regulatory milestones break.